Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Data used in preparation of this article were obtained
2024-10-30

Data used in preparation of this article were obtained from the ADNI database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing o
-
Among the enzymes involved in adenosine
2024-10-30

Among the enzymes involved in adenosine metabolism, adenosine kinase plays an important role in regulating formation and release of endogenous adenosine in cardiomyocytes as well as vascular endothelial cells Decking et al., 1997, Kowaluk et al., 1998, Smolenski et al., 1994. Inhibition of adenosine
-
The scattering operators associated to are defined
2024-10-29

The scattering operators associated to are defined as follows: for any and , , , there exists a unique solution to the following equation such that Then the scattering operator is defined by Here is an elliptic pseudodifferential operator of order , which is conformally covariant on the boundary.
-
Compounds were profiled for their inhibitory activity agains
2024-10-29

Compounds – were profiled for their inhibitory activity against dipeptidyl peptidase-IV Activity and/or Structure Homologues (DASH) [e.g. DPP2, DPP8 and DPP9] and non-DASH [eg. post-proline cleaving enzyme (PPCE), neutral endopeptidase (NEP), aminopeptidase P (APP), aminopeptidase N (APN)] enzymes.
-
Inhibitors of mPGES are considered as
2024-10-29

Inhibitors of mPGES-1 are considered as safe alternative to NSAIDs in the treatment of chronic inflammatory diseases that are characterized by excessive PGE2 production (Bahia et al., 2014; Khurana and Jachak, 2016; Koeberle et al., 2016; Korotkova and Jakobsson, 2014; Norberg et al., 2013; Psarra e
-
br Acknowledgements This work was
2024-10-29

Acknowledgements This work was supported by the FedEx Institute of Technology at The University of Memphis (to DLB and ALP), NSF REU CHE 1156738 (to ALP in support of RSS), and NIHCA921060 (to GT). This material is based upon work supported by the National Science Foundation under Grant No. CHE-1
-
While the yeasts and see Glossary each contain
2024-10-29

While the yeasts and (see Glossary) each contain only one Aurora homolog, Ipl1p (increase in ploidy 1) and Ark1 (Aurora-related kinase 1), respectively 5, 6, , and Xenopus laevis contain two Aurora kinases: Aurora A and Aurora B [4]. Mammals have three Aurora kinases, A, B, and C (Figure 1). In an
-
somatostatin agonist Aurora A the polar kinase
2024-10-29

Aurora A the ’polar kinase’ is located at the centrosome and is required for its maturation, division, for the mitotic spindle assembly and entry into mitosis., Mutation or transcriptional silencing of Aurora A impairs centrosome maturation and separation, leads to mono/multipolar spindles, to dela
-
AP activation is known to upregulate
2024-10-29

AP-1 activation is known to upregulate downstream target genes including MGCD0103 D1, c-myc, Bcl-xl, MMP-9, EGFR, and specific miRNAs that are involved in progression and metastasis of tumors. Moreover, matrix metalloproteinase-2 has been shown as a downstream gene of AP-1, triggered by 15-HETE in
-
br Acknowledgments br Introduction Cancer
2024-10-29

Acknowledgments Introduction Cancer is a deadly disease of uncontrolled cell division and has the potential to invade or spread to other parts of the body and affects normal functioning of the vital organs. Nowadays cancer is considered as leading cause of human death in all over the world and
-
br ROS in AiP and regeneration Tissue wounding
2024-10-29

ROS in AiP and regeneration Tissue wounding and inflammation are associated with production of ROS, and recent studies show that generation of ROS, especially during the initial stages of wounding and regeneration are essential for an efficient wound healing response. ROS, in particular H2O2 func
-
br Introduction Natural antioxidants in vegetables have gain
2024-10-29

Introduction Natural antioxidants, in vegetables, have gained the attention of both researchers and consumers. Vegetable amaranth (Amaranthus tricolor) is a good source of minerals, vitamins, phenolics, and carotenoids; it also contains betalains, a nitrogen containing group of natural pigments,
-
Tranexamic Acid br Acknowledgments and Disclosures br Introd
2024-10-29

Acknowledgments and Disclosures Introduction Over the last decade, the most visible strategy for the treatment of Alzheimer's disease (AD) has been amyloid β peptide (Aβ) immunotherapy (reviewed in [1]). Although the first efforts with Aβ immunotherapy failed to complete clinical trials [1], A
-
Our research group has been involved by many years in
2024-10-29

Our research group has been involved by many years in the synthesis of new 2,3-benzodiazepin-4-ones (e.g. 1, Fig. 1) and in the characterization of their mechanism of action.15, 16, 17 Within the development of these compounds, we demonstrated that an improvement of AMPAR antagonism by 2,3-benzodiaz
-
The beneficial treatment with several statins have
2024-10-28

The beneficial treatment with several statins have been evaluated in AD patients (Kivipelto et al., 2005), with controversial results. It has been suggested that statins slow cognitive decline in mild to moderate AD (Miida et al., 2005). Treatment with atorvastatin, combined with other medications,
16712 records 75/1115 page Previous Next First page 上5页 7172737475 下5页 Last page